Onapristone

Last updated
Onapristone
Onapristone.svg
Clinical data
Other namesZK-89299; ZK-299; AR-18; IVV-1001; 11β-(4-(Dimethylamino)phenyl)-17α-hydroxy-17β-(3-hydroxypropyl)-13α-estra-4,9-dien-3-one
Drug class Antiprogestogen
Identifiers
  • (8S,11R,13R,14S,17S)-11-[4-(Dimethylamino)phenyl]-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard 100.233.493 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C29H39NO3
Molar mass 449.635 g·mol−1
3D model (JSmol)
  • C[C@@]12C[C@@H](C3=C4CCC(=O)C=C4CC[C@H]3[C@@H]1CC[C@@]2(CCCO)O)C5=CC=C(C=C5)N(C)C
  • InChI=1S/C29H39NO3/c1-28-18-25(19-5-8-21(9-6-19)30(2)3)27-23-12-10-22(32)17-20(23)7-11-24(27)26(28)13-15-29(28,33)14-4-16-31/h5-6,8-9,17,24-26,31,33H,4,7,10-16,18H2,1-3H3/t24-,25+,26-,28+,29+/m0/s1
  • Key:IEXUMDBQLIVNHZ-YOUGDJEHSA-N

Onapristone (INN Tooltip International Nonproprietary Name) (developmental code names ZK-89299, ZK-299) is a synthetic and steroidal antiprogestogen with additional antiglucocorticoid activity which was developed by Schering [1] and described in 1984 but was never marketed. [2] [3] It is a silent antagonist of the progesterone receptor (PR), in contrast to the related antiprogestogen mifepristone (which is a weak partial agonist of the receptor). [4] Moreover, compared to mifepristone, onapristone has reduced antiglucocorticoid activity, shows little antiandrogenic activity, and has 10- to 30-fold greater potency as an antiprogestogen. [4] The medication was under development for clinical use, for instance in the treatment of breast cancer and as an endometrial contraceptive, but was discontinued during phase III clinical trials in 1995 due to findings that liver function abnormalities developed in a majority patients. [5] [6] [7]

Contents

Onapristone has been found to be effective in the treatment of breast cancer. [8] [5] [9]

As of 2016, onapristone has re-emerged and is under development for the treatment of prostate cancer, currently in phase II clinical trials. [10] It was also under development for the treatment of endometrial cancer, breast cancer, ovarian cancer, and uterine cancer, but was discontinued for these indications in favor of focusing on prostate cancer. [10]

Synthesis

Onapristone is an example of a retrosteroid - The inversion of stereochemistry at C13 is atypical of what is normally observed.

ChemDrug Synthesis: Patents: Onapristone synthesis.svg
ChemDrug Synthesis: Patents:

The conjugate addition reaction between PC10992393 (1) and 4-(n,n-Dimethyl)anilinemagnesium bromide [7353-91-5] (2) gives (3). Oxidation of the 17C alcohol group to a ketone gives [93748-54-0] (4). Irradiation for 16 minutes with a mercury lamp resulted in inversion of the methyl group from the beta to the alpha configuration, PC13371204 (5). Alkynylation with Tetrahydro-2-(2-propynyloxy)-2H-pyran [6089-04-9] (6) in the presence of butyl lithium gave (7). Catalytic hydrogenation then saturated the alkyne group whilst leaving the two olefins unperturbed. Acid removal of the cyclic ketal protecting group then completed the synthesis of onapristone (8).

See also

Related Research Articles

<span class="mw-page-title-main">Progesterone receptor</span> Cytoplasmic receptor protein found inside cells

The progesterone receptor (PR), also known as NR3C3 or nuclear receptor subfamily 3, group C, member 3, is a protein found inside cells. It is activated by the steroid hormone progesterone.

<span class="mw-page-title-main">Selective progesterone receptor modulator</span> Drug affecting hormone receptors

A selective progesterone receptor modulator (SPRM) is an agent that acts on the progesterone receptor (PR), the biological target of progestogens like progesterone. A characteristic that distinguishes such substances from full receptor agonists and full antagonists is that their action differs in different tissues, i.e. agonist in some tissues while antagonist in others. This mixed profile of action leads to stimulation or inhibition in tissue-specific manner, which further raises the possibility of dissociating undesirable adverse effects from the development of synthetic PR-modulator drug candidates.

<span class="mw-page-title-main">Tibolone</span> Chemical compound

Tibolone, sold under the brand name Livial among others, is a medication which is used in menopausal hormone therapy and in the treatment of postmenopausal osteoporosis and endometriosis. The medication is available alone and is not formulated or used in combination with other medications. It is taken by mouth.

<span class="mw-page-title-main">Asoprisnil</span> Chemical compound

Asoprisnil is a synthetic, steroidal selective progesterone receptor modulator that was under development by Schering and TAP Pharmaceutical Products for the treatment of uterine fibroids. In 2005, phase III clinical trials were discontinued due to endometrial changes in patients.

<span class="mw-page-title-main">Telapristone</span> Chemical compound

Telapristone, as telapristone acetate, is a synthetic, steroidal selective progesterone receptor modulator (SPRM) related to mifepristone which is under development by Repros Therapeutics for the treatment of breast cancer, endometriosis, and uterine fibroids. It was originally developed by the National Institutes of Health (NIH), and, as of 2017, is in phase II clinical trials for the aforementioned indications. In addition to its activity as an SPRM, the drug also has some antiglucocorticoid activity.

<span class="mw-page-title-main">Antiprogestogen</span> Class of compounds

Antiprogestogens, or antiprogestins, also known as progesterone antagonists or progesterone blockers, are a class of drugs which prevent progestogens like progesterone from mediating their biological effects in the body. These drugs competitively inhibit progestin at progesterone receptors. They act by blocking the progesterone receptor (PR)and/or inhibiting or suppressing progestogen production. Antiprogestogens are one of three types of sex hormone antagonists, the others being antiestrogens and antiandrogens.

<span class="mw-page-title-main">Dienogest</span> Chemical compound

Dienogest, sold under the brand name Visanne among others, is a progestin medication which is used in birth control pills and in the treatment of endometriosis. It is also used in menopausal hormone therapy and to treat heavy periods. Dienogest is available both alone and in combination with estrogens. It is taken by mouth.

<span class="mw-page-title-main">Promegestone</span> Chemical compound

Promegestone, sold under the brand name Surgestone, is a progestin medication which is used in menopausal hormone therapy and in the treatment of gynecological disorders. It is taken by mouth.

<span class="mw-page-title-main">Trimegestone</span> Chemical compound

Trimegestone, sold under the brand names Ondeva and Totelle among others, is a progestin medication which is used in menopausal hormone therapy and in the prevention of postmenopausal osteoporosis. It was also under development for use in birth control pills to prevent pregnancy, but ultimately was not marketed for this purpose. The medication is available alone or in combination with an estrogen. It is taken by mouth.

<span class="mw-page-title-main">Nomegestrol acetate</span> Chemical compound

Nomegestrol acetate (NOMAC), sold under the brand names Lutenyl and Zoely among others, is a progestin medication which is used in birth control pills, menopausal hormone therapy, and for the treatment of gynecological disorders. It is available both alone and in combination with an estrogen. NOMAC is taken by mouth. A birth control implant for placement under the skin was also developed but ultimately was not marketed.

<span class="mw-page-title-main">Segesterone acetate</span> Progestin medication

Segesterone acetate (SGA), sold under the brand names Nestorone, Elcometrine, and Annovera, is a progestin medication which is used in birth control and in the treatment of endometriosis in the United States, Brazil, and other South American countries. It is available both alone and in combination with an estrogen. It is not effective by mouth and must be given by other routes, most typically as a vaginal ring or implant that is placed into fat.

<span class="mw-page-title-main">Benorterone</span> Chemical compound

Benorterone, also known by its developmental code name SKF-7690 and as 17α-methyl-B-nortestosterone, is a steroidal antiandrogen which was studied for potential medical use but was never marketed. It was the first known antiandrogen to be studied in humans. It is taken by mouth or by application to skin.

A hormone-sensitive cancer, or hormone-dependent cancer, is a type of cancer that is dependent on a hormone for growth and/or survival. Examples include breast cancer, which is dependent on estrogens like estradiol, and prostate cancer, which is dependent on androgens like testosterone.

<span class="mw-page-title-main">Progesterone (medication)</span> Medication and naturally occurring steroid hormone

Progesterone (P4), sold under the brand name Prometrium among others, is a medication and naturally occurring steroid hormone. It is a progestogen and is used in combination with estrogens mainly in hormone therapy for menopausal symptoms and low sex hormone levels in women. It is also used in women to support pregnancy and fertility and to treat gynecological disorders. Progesterone can be taken by mouth, vaginally, and by injection into muscle or fat, among other routes. A progesterone vaginal ring and progesterone intrauterine device used for birth control also exist in some areas of the world.

<span class="mw-page-title-main">ZM-182345</span> Chemical compound

ZM-182345 is a nonsteroidal progestin that was never marketed. It was derived from structural modification of the nonsteroidal antiandrogen hydroxyflutamide. ZM-182345 was found to be at least as potent as progesterone as a progestogen in animals but to also possess androgenic activity.

<span class="mw-page-title-main">Toripristone</span> Chemical compound

Toripristone is a synthetic, steroidal antiglucocorticoid as well as antiprogestogen which was never marketed. It is reported as a potent and highly selective antagonist of the glucocorticoid receptor (GR), though it also acts as an antagonist of the progesterone receptor (PR). The pharmacological profile of toripristone is said to be very similar to that of mifepristone, except that toripristone does not bind to orosomucoid. The drug has been used to study the hypothalamic-pituitary-adrenal axis and has been used as a radiotracer for the GR. Its INN was given in 1990.

<span class="mw-page-title-main">Lilopristone</span> Chemical compound

Lilopristone (INN) is a synthetic, steroidal antiprogestogen with additional antiglucocorticoid activity which was developed by Schering and was patented in 1985. It is described as an abortifacient and endometrial contraceptive. The drug differs from mifepristone only in the structure of its C17α side chain, and is said to have much reduced antiglucocorticoid activity in comparison.

<span class="mw-page-title-main">Lonaprisan</span> Chemical compound

Lonaprisan is a synthetic, steroidal antiprogestogen which was under development by Bayer HealthCare Pharmaceuticals for the treatment of endometriosis, dysmenorrhea, and breast cancer but was discontinued. It is a potent and highly selective silent antagonist of the progesterone receptor (PR). The drug reached phase II clinical trials prior to its discontinuation.

The pharmacology of progesterone, a progestogen medication and naturally occurring steroid hormone, concerns its pharmacodynamics, pharmacokinetics, and various routes of administration.

References

  1. ↑ Lange CA, Sartorius CA, Abdel-Hafiz H, Spillman MA, Horwitz KB, Jacobsen BM (2008). "Progesterone receptor action: translating studies in breast cancer models to clinical insights". Advances in Experimental Medicine and Biology. Vol. 630. Springer. pp. 94–111. doi:10.1007/978-0-387-78818-0_7. ISBN   978-0-387-78817-3. PMID   18637487. Onapristone , p. 102, at Google Books
  2. ↑ Elks J, Ganellin CR (1990). "O". Dictionary of Drugs. Springer. pp. 892–927. doi:10.1007/978-1-4757-2085-3_15. ISBN   978-1-4757-2087-7. Onapristone , p. 903, at Google Books
  3. ↑ Morton IK, Hall JM (1999). "O". Concise Dictionary of Pharmacological Agents. Springer. pp. 206–213. doi:10.1007/978-94-011-4439-1_14. ISBN   978-94-010-5907-7. Onapristone , p. 207, at Google Books
  4. 1 2 Pavlik EJ, Nelson K, Srinivasan S, Depriest PD, Kenady DE (1997). "Antiestrogen Resistance in Human Breast Cancer". Estrogens, Progestins, and Their Antagonists. Hormones in Health and Disease. Birkhäuser. pp. 115–160. doi:10.1007/978-1-4612-4096-9_5. ISBN   978-1-4612-8650-9. Onapristone , p. 134, at Google Books
  5. 1 2 Robertson JF, Willsher PC, Winterbottom L, Blamey RW, Thorpe S (February 1999). "Onapristone, a progesterone receptor antagonist, as first-line therapy in primary breast cancer". European Journal of Cancer. 35 (2): 214–218. doi:10.1016/S0959-8049(98)00388-8. PMID   10448262.
  6. ↑ Katkam RR, Gopalkrishnan K, Chwalisz K, Schillinger E, Puri CP (September 1995). "Onapristone (ZK 98.299): a potential antiprogestin for endometrial contraception". American Journal of Obstetrics and Gynecology. 173 (3 Pt 1): 779–787. doi:10.1016/0002-9378(95)90341-0. PMID   7573244.
  7. ↑ Howell SJ, Howell A (2010). "Endocrine Therapy". Management of Breast Diseases. Springer. pp. 329–352. doi:10.1007/978-3-540-69743-5_18. ISBN   978-3-540-69742-8. Onapristone , p. 338, at Google Books
  8. ↑ Klijn JG, Setyono-Han B, Foekens JA (2000). "Progesterone antagonists and progesterone receptor modulators in the treatment of breast cancer". Steroids. 65 (10–11): 825–830. doi:10.1016/S0039-128X(00)00195-1. PMID   11108894. S2CID   25524094.
  9. ↑ Cottu PH, Bonneterre J, Varga A, Campone M, Leary A, Floquet A, et al. (2018). "Phase I study of onapristone, a type I antiprogestin, in female patients with previously treated recurrent or metastatic progesterone receptor-expressing cancers". PLOS ONE. 13 (10): e0204973. Bibcode:2018PLoSO..1304973C. doi: 10.1371/journal.pone.0204973 . PMC   6179222 . PMID   30304013.
  10. 1 2 "Onapristone - Context Therapeutics". Adis Insight. Springer Nature Switzerland AG.
  11. ↑ Pento, J.; Castaer, J.; Onapristone. Drugs Fut 1995, 20, 8, 784.
  12. ↑ Neef, Günter; Beier, Sybille; Elger, Walter; Henderson, David; Wiechert, Rudolf (1984). "New steroids with antiprogestational and antiglucocorticoid activities". Steroids. 44 (4): 349–372. doi:10.1016/S0039-128X(84)80027-6.
  13. ↑ Günter Dr. Neef, 6 More », EP0129499 (1987 to Schering Aktiengesellschaft).
  14. ↑ Ulf Tilstam, et al. WO2017053793 (to Context Biopharma Inc).
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.